Indiplon in the treatment of insomnia
Indiplon is a non-benzodiazepine sedative-hypnotic in the short duration of action. It 's a high-affinity allosteric enhancer of GABA-A receptor. E 'Indiplon has been shown that it binds to specific binding sites for BZ1 or GABA-A receptor alpha 1, differing from the classic benzodiazepines. A phase III To evaluate the efficacy and safety of Indiplon, immediate-release formulation, in 200 adult patients with chronic primary insomnia over a period of 35 days. Indiplon showed a statistically significant improvement nell'end primary endpoint of Latency to Persistent Sleep (LPS), a measure obtained by polysomnography. Treatment with LPS Indiplon 10mg reduced to 28 minutes (p <> Q). Rebound insomnia was not observed. A second phase III clinical trial with immediate-release Indiplon showed the achievement of primary and secondary end points in 593 subjects with transient insomnia. The primary end point was represented by Latency to Persistent Sleep (LPS), while the end secondary endpoint was to Latency to Sleep Onset (LSO). The improvements mean nell'end primary endpoint were 36% and 50% for the 10mg dose and 20mg, respectively. Patients also presented an improvement of Sleep Quality for both doses.
Source: Neurocrine Biosciences, 2006
0 comments:
Post a Comment